MCID: OVR012
MIFTS: 55

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 54 6 15 17 70
Serous Cystadenoma 12 17
Cystadenoma, Serous 70
Cystadenoma Serous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 50 C7978
UMLS 70 C0206709 C0279663

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as serous cystadenoma, is related to adenoma and clear cell adenofibroma. An important gene associated with Ovarian Serous Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Bevacizumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, breast and ovary, and related phenotypes are Increased cell death in HCT116 cells and cellular

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 adenoma 31.3 TP53 PIK3CA BRAF AKT1
2 clear cell adenofibroma 31.0 PPP2R1A PIK3CA
3 adenofibroma 30.7 TP53 MUC16 BRAF
4 uterine corpus endometrial carcinoma 30.6 TP53 PPP2R1A PIK3CA HRAS FBXW7
5 adenocarcinoma 30.6 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
6 cervical squamous cell carcinoma 30.6 VEGFA TP53 PIK3CA AKT1
7 pancreatic ductal adenocarcinoma 30.6 VEGFA TP53 ERBB2 AKT1
8 villous adenoma 30.5 TP53 HRAS BRAF
9 lobular neoplasia 30.5 TP53 PGR ERBB2
10 myoma 30.4 TP53 PGR MUC16
11 lymphangioma 30.4 VEGFA TP53 PIK3CA HRAS
12 mature teratoma 30.4 TP53 NANOG ERBB2 BRAF
13 carcinosarcoma 30.4 TP53 PPP2R1A PIK3CA PGR HRAS FBXW7
14 fallopian tube carcinoma 30.4 VEGFA TP53 PGR ERBB2
15 differentiated thyroid carcinoma 30.3 VEGFA TP53 NRAS HRAS BRAF
16 endometrial hyperplasia 30.3 VEGFA TP53 PGR
17 pancreatic ductal carcinoma 30.3 VEGFA TP53 MUC16 ERBB2
18 hemangioma 30.3 VEGFA TP53 PGR AKT1
19 uterine carcinosarcoma 30.3 TP53 PPP2R1A PIK3CA PGR LRRC56 HRAS
20 bile duct cancer 30.2 VEGFA TP53 HRAS ERBB2 AKT1
21 in situ carcinoma 30.2 TP53 PIK3CA PGR HRAS ERBB2 AKT1
22 cholangiocarcinoma 30.2 VEGFA TP53 PIK3CA ERBB2 BRAF AKT1
23 cystadenocarcinoma 30.1 ZNF217 YAP1 VEGFA TP53 PPP2R1A PIK3CA
24 serous cystadenocarcinoma 29.9 ZNF217 YAP1 VEGFA USP2 TP53 PPP2R1A
25 renal cell carcinoma, nonpapillary 29.9 VEGFA TP53 PIK3CA NRAS HRAS BRAF
26 pancreatic cancer 29.8 VEGFA TP53 PIK3CA NANOG MUC16 HRAS
27 ovarian cancer 29.7 VEGFA TP53 PIK3CA PGR MUC16 HRAS
28 endometrial cancer 29.5 VEGFA TP53 PPP2R1A PIK3CA PGR NRAS
29 lung cancer susceptibility 3 29.2 VEGFA TP53 PPP2R1A PIK3CA NRAS MUC16
30 pancreatic serous cystadenoma 11.7
31 serous cystadenoma of childhood 11.3
32 nevus of ota 10.5 TP53 BRAF
33 pancreatic signet ring cell adenocarcinoma 10.5 TP53 HRAS
34 myoepithelial carcinoma 10.5 TP53 PIK3CA HRAS
35 melphalan allergy 10.5 NRAS BRAF
36 meningeal melanomatosis 10.5 NRAS HRAS
37 bartholin's gland adenoma 10.5 TP53 PGR
38 bartholin's gland benign neoplasm 10.5 TP53 PGR
39 vestibular gland benign neoplasm 10.5 TP53 PGR
40 nonseminomatous germ cell tumor 10.5 ERBB2 BRAF
41 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
42 microcystic adenoma 10.5
43 vulvar intraepithelial neoplasia 10.5 TP53 BIRC5
44 endometrioid ovary carcinoma 10.5 TP53 PPP2R1A PIK3CA
45 acneiform dermatitis 10.5 NRAS HRAS BRAF
46 anus cancer 10.5 TP53 PIK3CA HRAS
47 ovarian carcinosarcoma 10.5 TP53 PIK3CA ERBB2
48 glassy cell carcinoma of the cervix 10.5 PGR ERBB2
49 breast intraductal papillomatosis 10.5 PGR ERBB2
50 nipple carcinoma 10.5 PGR ERBB2

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in HCT116 cells GR00103-A-0 8.8 FBXW7 PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 AKT1 B2M BIRC5 BRAF ERBB2 FBXW7
2 homeostasis/metabolism MP:0005376 10.38 AKT1 B2M BIRC5 BRAF ERBB2 FBXW7
3 cardiovascular system MP:0005385 10.36 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
4 endocrine/exocrine gland MP:0005379 10.34 AKT1 B2M BIRC5 BRAF ERBB2 FBXW7
5 embryo MP:0005380 10.32 AKT1 B2M BIRC5 BRAF ERBB2 FBXW7
6 mortality/aging MP:0010768 10.31 AKT1 B2M BIRC5 BRAF ERBB2 FBXW7
7 integument MP:0010771 10.23 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
8 digestive/alimentary MP:0005381 10.18 B2M BRAF ERBB2 FBXW7 HRAS NRAS
9 neoplasm MP:0002006 10.13 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
10 liver/biliary system MP:0005370 10.03 AKT1 B2M BRAF FBXW7 NRAS TP53
11 muscle MP:0005369 10.02 AKT1 BRAF ERBB2 HRAS PGR PIK3CA
12 normal MP:0002873 9.9 AKT1 BIRC5 BRAF ERBB2 FBXW7 HRAS
13 no phenotypic analysis MP:0003012 9.86 HRAS NANOG NRAS PGR PIK3CA TP53
14 reproductive system MP:0005389 9.65 AKT1 B2M BRAF ERBB2 LRRC56 PGR
15 respiratory system MP:0005388 9.23 AKT1 BRAF ERBB2 FBXW7 HRAS TP53

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
3
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
4
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7 Angiogenesis Inhibitors Phase 3
8 Antineoplastic Agents, Immunological Phase 3
9 Tubulin Modulators Phase 2, Phase 3
10 Antimitotic Agents Phase 2, Phase 3
11 Albumin-Bound Paclitaxel Phase 2, Phase 3
12 Antirheumatic Agents Phase 3
13 Immunosuppressive Agents Phase 3
14 Alkylating Agents Phase 3
15 Immunologic Factors Phase 3
16 Analgesics Phase 3
17
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
18
Lenograstim Approved, Investigational Phase 2 135968-09-1
19
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
20
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
21 topoisomerase I inhibitors Phase 2
22
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
23 Protein Kinase Inhibitors Phase 1, Phase 2
24 Antimetabolites Phase 2
25
Melphalan Approved Phase 1 148-82-3 4053 460612
26
Thiotepa Approved, Investigational Phase 1 52-24-4 5453
27
Iodine Approved, Investigational Phase 1 7553-56-2 807
28
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
29
Etoposide Approved Phase 1 33419-42-0 36462
30 Cola Phase 1
31 Immunotoxins Phase 1
32 Immunoglobulins Phase 1
33 Antibodies Phase 1
34 Immunoglobulins, Intravenous Phase 1
35 Liver Extracts Phase 1
36 Vaccines Phase 1
37 Antibodies, Monoclonal Phase 1
38
Liposomal doxorubicin Phase 1 31703
39 Antibiotics, Antitubercular Phase 1
40 Anti-Bacterial Agents Phase 1
41 Etoposide phosphate Phase 1
42
Pancrelipase Approved, Investigational 53608-75-6
43 Pharmaceutical Solutions
44 pancreatin

Interventional clinical trials:

(show all 38)
# Name Status NCT ID Phase Drugs
1 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
2 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
3 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
4 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
5 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
6 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
7 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
8 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
9 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
10 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
11 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
12 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
13 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
14 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
15 A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
16 A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum Terminated NCT00354601 Phase 2 capecitabine;docetaxel
17 Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary Withdrawn NCT00003865 Phase 2 toremifene
18 A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer Completed NCT00652691 Phase 1 carboplatin;cyclophosphamide;topotecan hydrochloride
19 A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
20 A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer Completed NCT00002977 Phase 1 melphalan;thiotepa
21 Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing Completed NCT00066651 Phase 1
22 A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
23 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
24 A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
25 A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
26 A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA Completed NCT00002600 Phase 1 carboplatin;cyclophosphamide
27 Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Completed NCT00408590 Phase 1
28 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
29 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
30 A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
31 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Unknown status NCT00897039
32 Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis Unknown status NCT00238342
33 Diagnosis of Pancreatic Cystic Lesions With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy Unknown status NCT03884179
34 A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas Completed NCT02523170
35 Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors. Recruiting NCT03305146
36 Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol Terminated NCT00904514
37 Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions Terminated NCT02494388
38 A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

40
Pancreas, Breast, Ovary, Lung, Thyroid, Skin, Kidney

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show top 50) (show all 988)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. 61 54
17309670 2007
3
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. 61 54
17160949 2006
4
Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease. 61 54
14627339 2003
5
[An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels]. 54 61
1506732 1992
6
Pancreatobiliary manifestations of nonalcoholic fatty liver disease: a retrospective case-control multicenter study. 61
32483086 2021
7
Calponin and MUC6 complement inhibin as diagnostic immunomarkers of serous cystadenoma in endoscopic ultrasound guided aspiration/biopsy specimens. 61
33657658 2021
8
Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort. 61
33787974 2021
9
Herlyn-Werner-Wunderlich syndrome with borderline serous cystadenoma of the ovary: case report and literature review. 61
33532015 2021
10
The expression and significance of leukemia inhibitory factor, interleukin-6 and vascular endothelial growth factor in Chinese patients with endometriosis. 61
33555431 2021
11
Characterization and clinical significance of the CADM1/HER2/STAT3 axis in serous ovarian tumors. 61
33663040 2021
12
Identification and analysis of RNA editing events in ovarian serous cystadenoma using RNA-seq Data. 61
33573552 2021
13
Triple threat: pancreatic cystic lesion presenting with spontaneous hemorrhage is found to harbor three distinct neoplasms. 61
33451339 2021
14
Systematic Profiling of Alternative Splicing Events in Ovarian Cancer. 61
33763357 2021
15
High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target. 61
33635867 2021
16
A Collision between Cavernous-Capillary Hemangioma with Stromal Luteinization and Serous Cystadenoma. 61
33415926 2020
17
A case of multiple serous cystadenoma of pancreas. 61
33299562 2020
18
Identification of key factors associated with early- and late-onset ovarian serous cystadenocarcinoma. 61
32885674 2020
19
Unexpected borderline ovarian tumours (BOT) in late pregnancy: challenges in management and review of literature. 61
33318250 2020
20
Diagnosing pancreatic serous cystadenoma on ThinPrep. 61
32374946 2020
21
Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers. 61
33247676 2020
22
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2020
23
Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer. 61
33231569 2020
24
OVARIAN CANCER TREATMENT OPTIMIZATION: THE COMPLEX ANALYSIS OF THE RESULTS OF CYTOREDUCTIVE SURGERY, MICROSCOPIC MALIGNANCY AND T-LYMPHOCYTIC INFILTRATION OF THE TUMOR. 61
33270572 2020
25
Role of volumetric multiparametric MRI in distinguishing between intraductal papillary mucinous neoplasms and serous cystadenoma. 61
33033892 2020
26
Ovarian tumors in children: how common are lesion recurrence and metachronous disease? A UK CCLG Surgeons Cancer Group nationwide study. 61
31837839 2020
27
Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression. 61
32866902 2020
28
Indocyanine Green-Enhanced Fluorescence in Laparoscopic Duodenum-Preserving Pancreatic Head Resection: Technique with Video. 61
32266569 2020
29
FBXW7γ is a tumor-suppressive and prognosis-related FBXW7 transcript isoform in ovarian serous cystadenocarcinoma. 61
32915667 2020
30
SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors. 61
32663767 2020
31
MONET: Multi-omic module discovery by omic selection. 61
32931516 2020
32
Discrimination of serous cystadenoma from mucinous cystic neoplasm and branch duct intraductal papillary mucinous neoplasm in the pancreas with CT. 61
32705313 2020
33
Incidentally detected microcystic serous cystadenoma of the pancreas with splenic invasion: a case report and literature review. 61
33029373 2020
34
Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer. 61
32880385 2020
35
The Study of the Expression of CGB1 and CGB2 in Human Cancer Tissues. 61
32957442 2020
36
Appendageal tumors and tumor-like lesions of the testis and paratestis: a 32-year experience at a single institution. 61
32619438 2020
37
Giant Paratubal Serous Cystadenoma in an Adolescent Female: Case Report and Literature Review. 61
32251838 2020
38
Laparoscopic Central Pancreatectomy with Pancreato-Gastric Anastomosis for Pancreatic Cystadenoma. 61
32876026 2020
39
[Robotic Surgery for Pancreatic Serous Cystadenoma: Analysis of 148 Cases]. 61
32691552 2020
40
Serous Cystadenoma of the Pancreas : Rare Presentation of Obstructive Jaundice. 61
32683932 2020
41
[Early experience of minimal invasive surgery for adolescent with pancreatic head tumor: a report of 15 cases]. 61
32610420 2020
42
Chemoresistance-associated alternative splicing signatures in serous ovarian cancer. 61
32565967 2020
43
Giant paratubal cyst presenting as adnexal torsion: A case report. 61
32714842 2020
44
The Utility of Endoscopic Ultrasound Fine Needle Aspiration in Pancreatic Cystic Lesions Diagnosis. 61
32707780 2020
45
Solid pseudopapillary tumour should be part of differential diagnosis of focal pancreatic lesions with increased 18 F-FDOPA uptake. 61
32314437 2020
46
[Clinical diagnosis and treatment characteristics of pancreatic cystic neoplasms in pediatric patients: a report of 13 cases]. 61
32610423 2020
47
A giant ovarian mass in a 68-year-old female with persistent abdominal pain and elevated serum CA-125 level. 61
32802022 2020
48
Survey and comparative assessments of computational multi-omics integrative methods with multiple regulatory networks identifying distinct tumor compositions across pan-cancer data sets. 61
32533167 2020
49
Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. 61
32356124 2020
50
Ancestry-specific predisposing germline variants in cancer. 61
32471518 2020

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show top 50) (show all 225)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His) SNV Likely pathogenic 376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
2 TP53 NM_000546.5(TP53):c.843C>G (p.Asp281Glu) SNV Likely pathogenic 376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777
3 TP53 NM_000546.5(TP53):c.646G>T (p.Val216Leu) SNV Likely pathogenic 376670 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
4 ERBB2 NM_004448.3(ERBB2):c.929C>T (p.Ser310Phe) SNV Likely pathogenic 376189 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
5 TP53 NM_000546.5(TP53):c.647T>A (p.Val216Glu) SNV Likely pathogenic 376672 rs1057520004 GRCh37: 17:7578202-7578202
GRCh38: 17:7674884-7674884
6 TP53 NM_000546.6(TP53):c.820G>T SNV Likely pathogenic 376674 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
7 TP53 NM_000546.6(TP53):c.797G>A (p.Gly266Glu) SNV Likely pathogenic 161516 rs193920774 GRCh37: 17:7577141-7577141
GRCh38: 17:7673823-7673823
8 TP53 NM_000546.5(TP53):c.580C>T (p.Leu194Phe) SNV Likely pathogenic 127817 rs587780071 GRCh37: 17:7578269-7578269
GRCh38: 17:7674951-7674951
9 TP53 NM_001276697.2(TP53):c.-46G>T SNV Likely pathogenic 376648 rs786201419 GRCh37: 17:7578498-7578498
GRCh38: 17:7675180-7675180
10 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro) SNV Likely pathogenic 237954 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
11 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely pathogenic 376416 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
12 TP53 NM_000546.5(TP53):c.839G>T (p.Arg280Ile) SNV Likely pathogenic 161517 rs121912660 GRCh37: 17:7577099-7577099
GRCh38: 17:7673781-7673781
13 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely pathogenic 177791 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
14 TP53 NM_000546.5(TP53):c.734G>A (p.Gly245Asp) SNV Likely pathogenic 12355 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
15 TP53 NM_000546.5(TP53):c.815T>G (p.Val272Gly) SNV Likely pathogenic 233323 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
16 TP53 NM_000546.5(TP53):c.658T>C (p.Tyr220His) SNV Likely pathogenic 376687 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
17 TP53 NM_000546.5(TP53):c.711G>A (p.Met237Ile) SNV Likely pathogenic 142714 rs587782664 GRCh37: 17:7577570-7577570
GRCh38: 17:7674252-7674252
18 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely pathogenic 376414 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
19 B2M NM_004048.3(B2M):c.1A>G (p.Met1Val) SNV Likely pathogenic 376369 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
20 TP53 NM_000546.5(TP53):c.730G>A (p.Gly244Ser) SNV Likely pathogenic 376600 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233
21 TP53 NM_000546.5(TP53):c.581T>A (p.Leu194His) SNV Likely pathogenic 376634 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
22 TP53 NM_000546.5(TP53):c.746G>A (p.Arg249Lys) SNV Likely pathogenic 142241 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
23 TP53 NM_000546.5(TP53):c.734G>T (p.Gly245Val) SNV Likely pathogenic 376603 rs121912656 GRCh37: 17:7577547-7577547
GRCh38: 17:7674229-7674229
24 TP53 NM_000546.5(TP53):c.821T>C (p.Val274Ala) SNV Likely pathogenic 376677 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
25 TP53 NM_000546.5(TP53):c.646G>A (p.Val216Met) SNV Likely pathogenic 182965 rs730882025 GRCh37: 17:7578203-7578203
GRCh38: 17:7674885-7674885
26 TP53 NM_000546.5(TP53):c.581T>G (p.Leu194Arg) SNV Likely pathogenic 376633 rs1057519998 GRCh37: 17:7578268-7578268
GRCh38: 17:7674950-7674950
27 TP53 NM_000546.5(TP53):c.809T>G (p.Phe270Cys) SNV Likely pathogenic 376597 rs1057519986 GRCh37: 17:7577129-7577129
GRCh38: 17:7673811-7673811
28 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys) SNV Likely pathogenic 69961 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
29 TP53 NM_000546.5(TP53):c.526T>G (p.Cys176Gly) SNV Likely pathogenic 376571 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
30 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu) SNV Likely pathogenic 376673 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
31 TP53 NM_000546.5(TP53):c.451C>A (p.Pro151Thr) SNV Likely pathogenic 12369 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
32 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val) SNV Likely pathogenic 182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
33 TP53 NM_000546.5(TP53):c.746G>C (p.Arg249Thr) SNV Likely pathogenic 376015 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
34 TP53 NM_000546.5(TP53):c.585C>G (p.Ile195Met) SNV Likely pathogenic 376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
35 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys) SNV Likely pathogenic 12349 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
36 HRAS , LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
37 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro) SNV Likely pathogenic 376659 rs730882008 GRCh37: 17:7577093-7577093
GRCh38: 17:7673775-7673775
38 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely pathogenic 376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
39 B2M NM_004048.3(B2M):c.3G>A (p.Met1Ile) SNV Likely pathogenic 376368 rs1057519877 GRCh37: 15:45003747-45003747
GRCh38: 15:44711549-44711549
40 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp) SNV Likely pathogenic 376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
41 TP53 NM_001276697.2(TP53):c.-26C>G SNV Likely pathogenic 376640 rs1057520000 GRCh37: 17:7578478-7578478
GRCh38: 17:7675160-7675160
42 TP53 NM_000546.5(TP53):c.814G>A (p.Val272Met) SNV Likely pathogenic 185814 rs121912657 GRCh37: 17:7577124-7577124
GRCh38: 17:7673806-7673806
43 TP53 NM_000546.5(TP53):c.613T>A (p.Tyr205Asn) SNV Likely pathogenic 376684 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
44 TP53 NM_000546.5(TP53):c.745A>T (p.Arg249Trp) SNV Likely pathogenic 141881 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
45 TP53 NM_000546.5(TP53):c.707A>G (p.Tyr236Cys) SNV Likely pathogenic 376693 rs730882026 GRCh37: 17:7577574-7577574
GRCh38: 17:7674256-7674256
46 TP53 NM_000546.5(TP53):c.645T>G (p.Ser215Arg) SNV Likely pathogenic 376661 rs1057520001 GRCh37: 17:7578204-7578204
GRCh38: 17:7674886-7674886
47 PPP2R1A NM_014225.6(PPP2R1A):c.547C>G (p.Arg183Gly) SNV Likely pathogenic 376507 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
48 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser) SNV Likely pathogenic 12383 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
49 TP53 NM_000546.5(TP53):c.526T>C (p.Cys176Arg) SNV Likely pathogenic 376573 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
50 TP53 NM_000546.5(TP53):c.730G>C (p.Gly244Arg) SNV Likely pathogenic 376602 rs1057519989 GRCh37: 17:7577551-7577551
GRCh38: 17:7674233-7674233

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.29 YAP1 VEGFA USP2 TP53 PPP2R1A PIK3CA
2
Show member pathways
14.13 VEGFA TP53 PPP2R1A PIK3CA NRAS NANOG
3
Show member pathways
13.84 PPP2R1A PIK3CA NRAS MUC16 HRAS FBXW7
4
Show member pathways
13.82 VEGFA TP53 PPP2R1A NRAS HRAS ERBB2
5
Show member pathways
13.66 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
6
Show member pathways
13.62 VEGFA PPP2R1A PIK3CA NRAS NANOG HRAS
7
Show member pathways
13.58 TP53 PPP2R1A PIK3CA NRAS HRAS FBXW7
8
Show member pathways
13.42 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
9
Show member pathways
13.39 YAP1 VEGFA PPP2R1A NRAS NANOG HRAS
10
Show member pathways
13.33 TP53 PPP2R1A PIK3CA NRAS HRAS BRAF
11
Show member pathways
13.21 VEGFA TP53 PPP2R1A PIK3CA NRAS NANOG
12
Show member pathways
13.2 VEGFA TP53 PIK3CA NRAS HRAS BIRC5
13
Show member pathways
13.14 VEGFA PPP2R1A PIK3CA NRAS HRAS AKT1
14
Show member pathways
13.11 VEGFA TP53 NRAS HRAS BRAF AKT1
15
Show member pathways
13.09 VEGFA TP53 PPP2R1A PIK3CA NRAS HRAS
16
Show member pathways
13.07 VEGFA TP53 PIK3CA NRAS HRAS B2M
17
Show member pathways
13.03 VEGFA PIK3CA NRAS HRAS ERBB2 BRAF
18
Show member pathways
12.99 PIK3CA NRAS HRAS ERBB2 BRAF AKT1
19
Show member pathways
12.98 VEGFA PIK3CA NRAS HRAS BRAF AKT1
20
Show member pathways
12.95 PIK3CA NRAS HRAS BRAF AKT1
21
Show member pathways
12.95 TP53 NRAS HRAS ERBB2 BRAF AKT1
22
Show member pathways
12.9 PPP2R1A NRAS HRAS BRAF AKT1
23 12.89 VEGFA TP53 NRAS HRAS ERBB2 BRAF
24
Show member pathways
12.88 PIK3CA HRAS BRAF BIRC5 AKT1
25
Show member pathways
12.87 VEGFA PIK3CA NRAS HRAS BRAF AKT1
26 12.86 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
27
Show member pathways
12.85 TP53 PPP2R1A PIK3CA NRAS HRAS ERBB2
28
Show member pathways
12.84 TP53 PIK3CA NRAS HRAS BIRC5 AKT1
29
Show member pathways
12.82 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
30
Show member pathways
12.82 TP53 PIK3CA PGR NRAS HRAS ERBB2
31
Show member pathways
12.8 TP53 PPP2R1A NRAS HRAS BRAF AKT1
32
Show member pathways
12.79 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
33
Show member pathways
12.78 VEGFA NRAS HRAS BRAF AKT1
34
Show member pathways
12.78 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
35
Show member pathways
12.77 PIK3CA NRAS HRAS BRAF AKT1
36
Show member pathways
12.71 VEGFA PIK3CA NRAS HRAS AKT1
37
Show member pathways
12.71 PPP2R1A PIK3CA NRAS HRAS BRAF
38 12.67 VEGFA TP53 PIK3CA NRAS HRAS ERBB2
39
Show member pathways
12.63 YAP1 TP53 PIK3CA NRAS HRAS ERBB2
40
Show member pathways
12.62 TP53 PPP2R1A PIK3CA HRAS AKT1
41
Show member pathways
12.61 PIK3CA NRAS HRAS ERBB2 AKT1
42
Show member pathways
12.58 TP53 PIK3CA NRAS HRAS ERBB2 AKT1
43
Show member pathways
12.57 TP53 PIK3CA NRAS HRAS ERBB2 BRAF
44
Show member pathways
12.55 VEGFA PIK3CA NRAS HRAS AKT1
45
Show member pathways
12.55 PIK3CA NRAS HRAS BRAF AKT1
46
Show member pathways
12.54 VEGFA PIK3CA HRAS BRAF AKT1
47
Show member pathways
12.53 TP53 PIK3CA HRAS BIRC5 AKT1
48
Show member pathways
12.51 PIK3CA NRAS HRAS AKT1
49
Show member pathways
12.5 PIK3CA NRAS HRAS AKT1
50
Show member pathways
12.5 PIK3CA NRAS HRAS ERBB2 BRAF

GO Terms for Ovarian Serous Cystadenocarcinoma

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 ZNF217 ZFHX4 YAP1 USP2 TP53 PPP2R1A

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.09 ZNF217 YAP1 VEGFA USP2 TP53 NANOG
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 YAP1 VEGFA TP53 PGR NANOG HRAS
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 VEGFA HRAS FBXW7 BRAF
4 positive regulation of cell proliferation GO:0008284 9.88 YAP1 VEGFA HRAS ERBB2 BIRC5 AKT1
5 positive regulation of protein phosphorylation GO:0001934 9.87 VEGFA HRAS ERBB2 AKT1
6 Ras protein signal transduction GO:0007265 9.78 TP53 NRAS HRAS
7 positive regulation of endothelial cell proliferation GO:0001938 9.77 VEGFA NRAS AKT1
8 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.76 VEGFA BIRC5 AKT1
9 negative regulation of neuron apoptotic process GO:0043524 9.76 PIK3CA HRAS BRAF BIRC5
10 vasculogenesis GO:0001570 9.73 YAP1 VEGFA FBXW7
11 somatic stem cell population maintenance GO:0035019 9.72 YAP1 NANOG BRAF
12 positive regulation of MAP kinase activity GO:0043406 9.69 VEGFA HRAS ERBB2
13 epidermal growth factor receptor signaling pathway GO:0007173 9.65 PIK3CA BRAF AKT1
14 cytokine-mediated signaling pathway GO:0019221 9.63 VEGFA TP53 PIK3CA NANOG BIRC5 AKT1
15 positive regulation of organ growth GO:0046622 9.62 YAP1 AKT1
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.62 VEGFA PIK3CA BRAF AKT1
17 anoikis GO:0043276 9.61 PIK3CA AKT1
18 phosphatidylinositol 3-kinase signaling GO:0014065 9.61 PIK3CA ERBB2 AKT1
19 progesterone receptor signaling pathway GO:0050847 9.59 YAP1 PGR
20 positive regulation of epithelial cell proliferation GO:0050679 9.56 YAP1 VEGFA HRAS ERBB2
21 cellular response to gamma radiation GO:0071480 9.54 YAP1 TP53 HRAS
22 circadian behavior GO:0048512 9.52 USP2 TP53
23 positive regulation of gene expression GO:0010628 9.5 YAP1 VEGFA TP53 HRAS ERBB2 BRAF
24 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.49 VEGFA TP53
25 negative regulation of gene expression GO:0010629 9.17 YAP1 VEGFA TP53 PGR HRAS FBXW7

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 ZNF217 YAP1 VEGFA USP2 TP53 PPP2R1A
2 identical protein binding GO:0042802 9.32 VEGFA USP2 TP53 PGR FBXW7 ERBB2
3 transcription regulatory region sequence-specific DNA binding GO:0000976 9.26 ZNF217 YAP1 TP53 NANOG

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....